An NIA-funded biotech company may be one step closer to developing a blood-based diagnostic for Alzheimer’s disease. This biotech company, Amprion, recently received a Breakthrough Device Designation by the FDA for a test developed to detect the alpha-synuclein protein in the cerebrospinal fluid and bloodstream, a known biomarker for Parkinson’s disease. Such designation by the FDA paves the way for faster development, assessment, and review, and potentially FDA approval of the technology. Small Business grants from the NIA are enabling Amprion to adopt their test to specifically detect traces of two biomarkers for Alzheimer’s disease, amyloid and tau aggregates, in cerebrospinal fluid and the bloodstream. With this new FDA designation for their technology, this company may be on track to develop a test that could help facilitate early detection and diagnosis of these devasting diseases.
On Monday, July 29th, the NIH released its FY2021 Professional Judgment Budget Proposal for Alzheimer’s Disease and Related Dementias Research. This document — often referred to as the Alzheimer’s disease “bypass budget” (ADBB) because it is presented without modification through the traditional Federal budget process — estimates the funds needed to fully pursue scientific opportunities leading to a cure for Alzheimer’s disease and related dementias. You can access the budget and related documents here.
Also, earlier today, the NIA hosted a webinar to discuss the ADBB process and purpose in greater depth, and to answer questions; we thank all who were able to join. If you were unable to participate, you can view/listen to the recording of the webinar here.
In June, Dr. Francis Collins, NIH Director, released a statement indicating that he would no longer participate in so-called “manels,” or all-male speaking panels. Before accepting any speaking invitation, Dr. Collins now assesses the extent to which women and other groups typically underrepresented in science are included on the event agenda. Consistent with Dr. Collins’ decision, Dr. Richard Hodes, NIA Director, is also committing to assessing the inclusivity of an event’s agenda before accepting an invitation to speak. Dr. Hodes announced his commitment to inclusivity and diversity at scientific meetings and conferences in a recent statement.
FoNIA is grateful for the Senate Subcommittee on Labor, Health and Human Services, and Education, and Related Agencies’ continued commitment to the mission of National Institutes of Health (NIH), and, in particular, the research supported and conducted by the National Institute on Aging (NIA). Friends of NIA (FoNIA) respectfully request at least $41.6 billion in funding for the NIH. Within this amount, we request that an increase of $500 million over FY 2019 levels be designated in support of cross-Institute aging research initiatives. In addition, the FONIA requests an increase of at least $350 million above the final enacted amount for FY 2019 for AD/ADRD research at the NIH.
|Friends of the National Institute on Aging presents an educational briefing|
|The Science of Aging|
Groundbreaking Research Supported by the National Institute on Aging (NIA)
Richard Hodes, MD
Marie A. Bernard, MD
Deputy Director, NIA
Sarah L. Szanton, PhD, ANP, FAAN
Director, Center on Innovative Care in Aging
Johns Hopkins School of Nursing
|Thursday, June 27, 2019 | 2:00pm – 3:00pm |
United States Capitol Visitor Center
Congressional Meeting Room North | CVC 268
First Street NE, Washington, DC 20515
|Refreshments (Ice Cream!) will be served.|
This event was planned to comply with House and Senate Ethics Rules.
This event is hosted by: